Biogen slashes price of Alzheimer’s drug Aduhelm in half, plans $500M in cost-cutting
Biogen said Monday that it has reduced the price of its Alzheimer’s drug Aduhelm by half and is planning a series of cost-cutting measures across the company next year that aim to save $500 million.
The moves follow a disappointing commercial launch of Aduhelm, as well as anger over the drug’s high price.
